Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer

被引：29

作者：

Drachman, Jonathan G. ^{[1
]}

Senter, Peter D. ^{[1
]}

机构：

[1] Seattle Genet Inc, Bothell, WA 98021 USA

来源：

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM | 2013年

关键词：

ACUTE MYELOID-LEUKEMIA; SITE-SPECIFIC CONJUGATION; GEMTUZUMAB OZOGAMICIN; BRENTUXIMAB VEDOTIN; ANTITUMOR-ACTIVITY; TRASTUZUMAB EMTANSINE; THERAPY; CHALLENGES; INDUCTION; LYMPHOMA;

D O I：

10.1182/asheducation-2013.1.306

中图分类号：

G40 [教育学];

学科分类号：

040101 ; 120403 ;

摘要：

For more than a century, the concept of a "magic bullet" to deliver cytotoxic therapy to the site of disease has been envisioned but only recently have technological advances enabled antibody-drug conjugates to fulfill that dream. The recent approvals of brentuximab vedotin and ado-trastuzumab emtansine and emerging data for many molecules in clinical trials highlight the potential for antibody-drug conjugates to offer new therapeutic options for patients. This chapter reviews the evolution, state of the art, and potential future improvements that are enabling rapid development of this important class of cancer therapeutics.

引用

页码：306 / 310

页数：5

共 36 条

[1] Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples [J].

Boghaert, Erwin R. ;

Khandke, Kiran M. ;

Sridharan, Latha ;

Dougher, Maureen ;

DiJoseph, John F. ;

Kunz, Arthur ;

Hamann, Philip R. ;

Moran, Justin ;

Chaudhary, Inder ;

Damle, Nitin K. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (06) :1027-1035

[2]

Bross PF, 2001, CLIN CANCER RES, V7, P1490

[3] Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia [J].

Burnett, Alan K. ;

Russell, Nigel H. ;

Hills, Robert K. ;

Kell, Jonathan ;

Freeman, Sylvie ;

Kjeldsen, Lars ;

Hunter, Ann E. ;

Yin, John ;

Craddock, Charles F. ;

Dufva, Inge Hoegh ;

Wheatley, Keith ;

Milligan, Donald .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (32) :3924-3931

[4] Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial [J].

Burnett, Alan K. ;

Hills, Robert K. ;

Milligan, Donald ;

Kjeldsen, Lars ;

Kell, Jonathan ;

Russell, Nigel H. ;

Yin, John A. L. ;

Hunter, Ann ;

Goldstone, Anthony H. ;

Wheatley, Keith .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) :369-377

[5] Antibody-drug conjugates for cancer therapy [J].

Carter, Paul J. ;

Senter, Peter D. .

CANCER JOURNAL, 2008, 14 (03) :154-169

[6] Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study [J].

Castaigne, Sylvie ;

Pautas, Cecile ;

Terre, Christine ;

Raffoux, Emmanuel ;

Bordessoule, Dominique ;

Bastie, Jean-Noel ;

Legrand, Ollivier ;

Thomas, Xavier ;

Turlure, Pascal ;

Reman, Oumedaly ;

de Revel, Thierry ;

Gastaud, Lauris ;

de Gunzburg, Noemie ;

Contentin, Nathalie ;

Henry, Estelle ;

Marolleau, Jean-Pierre ;

Aljijakli, Ahmad ;

Rousselot, Philippe ;

Fenaux, Pierre ;

Preudhomme, Claude ;

Chevret, Sylvie ;

Dombret, Herve .

LANCET, 2012, 379 (9825) :1508-1516

[7] Targeted cancer therapy: Conferring specificity to cytotoxic drugs [J].

Chari, Ravi V. J. .

ACCOUNTS OF CHEMICAL RESEARCH, 2008, 41 (01) :98-107

[8] Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study [J].

Delaunay, Jacques ;

Recher, Christian ;

Pigneux, Arnaud ;

Witz, Francis ;

Vey, Norbert ;

Blanchet, Odile ;

Lefebvre, Pascale ;

Luquet, Isabelle ;

Guillerme, Isabelle ;

Volteau, Christelle ;

Gyan, Emmanuel ;

Lioure, Bruno ;

Jourdan, Eric ;

Bouscary, Didier ;

Guieze, Romain ;

Randriamalala, Edouard ;

Uribe, Mario E. Ojeda ;

Dreyfus, Francois ;

Lacombe, Catherine ;

Bene, Marie-christine ;

Cahn, Jean-Yves ;

Harousseau, Jean-Luc ;

Ifrah, Norbert .

BLOOD, 2011, 118 (21) :37-38

[9] TARGETED TOXIN THERAPY FOR THE TREATMENT OF CANCER [J].

FITZGERALD, D ;

PASTAN, I .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (19) :1455-1463

[10] An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker [J].

Hamann, PR ;

Hinman, LM ;

Beyer, CF ;

Lindh, D ;

Upeslacis, J ;

Flowers, DA ;

Bernstein, I .

BIOCONJUGATE CHEMISTRY, 2002, 13 (01) :40-46

← 1 2 3 4 →